Sionna Therapeutics Strengthens Leadership Team With Appointment Of Caroline Stark Beer As Chief Business Officer

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing new therapies for cystic fibrosis, has announced the appointment of Caroline Stark Beer, MBA, as Chief Business Officer. In her new role, Caroline will oversee corporate and business development, partnerships, and strategic initiatives as Sionna advances its mission to normalize CFTR protein function and transform treatment for people living with cystic fibrosis.

Caroline brings more than two decades of experience in the life sciences industry. She most recently served as Chief Business Officer at Jnana Therapeutics, where she led business and corporate development, alliance management, legal, new product planning, and communications. She played a key role in guiding the company through its recent acquisition by Otsuka Pharmaceutical.

Mike Cloonan, President and Chief Executive Officer of Sionna, stated, “We are delighted to welcome Caroline to our executive team at such a pivotal stage for Sionna. Caroline’s exceptional experience, leadership, and value creation mindset will enhance our corporate development efforts as we continue to advance toward our goal of delivering innovative and transformative therapies for people living with CF.”

Caroline mentioned, “I believe that the most meaningful growth happens in organizations where scientific excellence and business strategy work seamlessly together while focusing on the patient as the North-Star. Sionna embodies this approach, which is why I’m thrilled to join the company. I look forward to helping Sionna execute on its mission, striving toward enhanced options for CF patients.”

Before joining Jnana, Caroline spent over 10 years at Alnylam Pharmaceuticals, ultimately serving as Vice President of Business Development. During her tenure, she spearheaded multiple strategic collaborations, including a significant five-year partnership with Regeneron Pharmaceuticals to advance RNA interference-based therapies. Earlier in her career, she worked in business development at Amicus Therapeutics and began her professional journey as a strategy consultant at Bain & Company.

Caroline holds an MBA from the MIT Sloan School of Management and a Bachelor’s degree in Economics from Duke University. Her appointment strengthens Sionna’s leadership team as the company continues to advance its pipeline of novel CF therapies aimed at addressing the underlying cause of the disease.